Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Methylprednisolone
Drug ID BADD_D01433
Description Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone].[A188811] It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957.[L10785] In the outbreak of COVID-19, low dose methylprednisolone-based therapy was successful in treating COVID-19-associated pneumonia in one patient with long-term immunosuppression.[A192813] The efficacy of methylprednisolone in novel coronavirus pneumonia is being investigated further in clinical trials.[L12666]
Indications and Usage Adjunctive therapy for short-term administration in rheumatoid arthritis.
Marketing Status Prescription; Discontinued
ATC Code D07AA01; D10AA02; H02AB04
DrugBank ID DB00959
KEGG ID D00407
MeSH ID D008775
PubChem ID 6741
TTD Drug ID D08PIQ
NDC Product Code 69306-400; 0009-0038; 68071-5221; 71329-303; 68180-686; 57582-011; 0009-0022; 68788-4593; 22552-0029; 68382-918; 71329-305; 68180-687; 70121-1000; 82094-401; 70121-1001; 61919-149; 59746-002; 70518-1541; 68788-7833; 63629-2226; 45865-104; 68071-2370; 82094-405; 82094-403; 65162-980; 59762-0051; 70625-237; 63629-2218; 49999-153; 76420-041; 68071-2301; 59762-0049; 0009-0073; 76420-193; 68382-916; 59746-003; 71329-302; 82094-402; 71205-054; 63187-802; 59762-4440; 71205-453; 70771-1350; 59746-001; 71329-301; 70771-1351; 68180-689; 42806-400; 0781-5022; 72647-331; 60722-1003; 82094-404; 51552-0603; 68001-005; 51927-0201; 49452-4686; 68382-917; 70771-1348; 71329-304; 68382-919; 0603-4593; 65162-871; 59762-0050; 60760-373; 70786-0001; 65162-982; 70771-1349; 0009-0056; 50436-0001; 57582-101; 0009-0020; 0009-0176; 68071-4028; 59746-015; 64958-0084; 53002-3120; 82298-118; 63629-2433; 72189-264; 65162-984; 0904-6914; 69306-004; 63187-160; 50090-3811; 68084-149; 55289-649; 50090-0092; 45865-417; 50090-3094; 68180-688; 68180-685; 66267-961
Synonyms Methylprednisolone | Metipred | 6-Methylprednisolone | 6 Methylprednisolone | Urbason | Medrol
Chemical Information
Molecular Formula C22H30O5
CAS Registry Number 83-43-2
SMILES CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)CO)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
HepatotoxicityTyrosine aminotransferaseP17735Not Available10485078; 10098101; 8719235; 1362219
HepatotoxicityGlucocorticoid receptorP04150T4001610485078; 10098101; 8719235; 1362219
Immune thrombocytopenic purpuraInterleukin-6P05231T32578Not Available
Immune thrombocytopenic purpuraThrombopoietinP40225T99379Not Available
Immune thrombocytopenic purpuraP-selectinP16109T10965Not Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Leukoderma23.05.02.001--Not Available
Leukopenia01.02.02.0010.000212%Not Available
Lip oedema07.05.04.004; 23.04.01.006; 10.01.05.0040.000142%Not Available
Lip swelling23.04.01.007; 10.01.05.005; 07.05.04.0050.000142%Not Available
Local swelling08.01.03.0130.000212%Not Available
Loss of consciousness17.02.04.0040.000495%Not Available
Lung disorder22.02.07.0010.000142%Not Available
Lymphadenopathy01.09.01.0020.000142%Not Available
Lymphangitis24.09.02.001; 11.01.15.001; 01.09.01.0050.000142%Not Available
Malaise08.01.01.003--
Mania19.16.02.002--
Melaena24.07.02.013; 07.12.02.0040.000212%Not Available
Memory impairment19.20.01.003; 17.03.02.003--
Meningitis17.06.03.001; 11.01.03.0010.000991%
Meningitis bacterial17.06.10.002; 11.02.01.0130.000055%Not Available
Meningitis meningococcal17.06.10.001; 11.02.14.0040.000142%Not Available
Meningitis viral17.06.08.001; 11.05.04.0090.000212%Not Available
Menstruation irregular21.01.01.005; 05.05.01.008--
Metabolic acidosis14.01.01.003--Not Available
Metastases to liver09.04.02.004; 16.22.02.0010.000142%Not Available
Migraine24.03.05.003; 17.14.02.0010.000212%Not Available
Miliaria23.02.03.014--Not Available
Monoplegia17.01.04.003--Not Available
Mood swings19.04.03.001--Not Available
Multiple fractures15.08.02.005; 12.04.02.009--Not Available
Muscle atrophy17.05.03.004; 15.05.03.0030.000212%Not Available
Muscle disorder15.05.03.0140.000354%Not Available
Muscle spasms15.05.03.004--
Muscular weakness17.05.03.005; 15.05.06.0010.000283%
Musculoskeletal pain15.03.04.0070.000283%
The 7th Page    First    Pre   7 8 9 10 11    Next   Last    Total 15 Pages